Growth Opportunities in “United States Influenza Vaccine Market” Industry: Trends, Forecast and Opportunity Analysis by Top Manufacturers, Trends, Application by 2022

United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022.
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.
Browse full table of contents and data tables at : http://www.dpiresearch.com/report-details.php?P_ID=90
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It provides essential insights into United States influenza vaccine market and forecast. It covers vaccination pattern, doses distribution, production and offers a clear view of the regulatory landscape. Additionally, the report includes insight of clinical trials, pipeline and promising vaccines in United States influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.
The report concludes with the profiles of major players in the influenza vaccine market such as Sanofi Pasteur, GSK, Seqirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The report also entails major drivers and barriers of influenza vaccine market.
Major and Promising Vaccine covered in the report are as follows:
Fluzone High–Dose
Fluzone Quadrivalent
Intradermal (ID) Trivalent
Vaxigrip
Fluarix Quadrivalent
Flulaval Quadrivalent
Fluenz Tetra
FluMist Quadrivalent
Flublok
VN–100
M–001
VAX–2012Q
TAK – 850
Flucelvax Quadrivalent
Afluria Quadrivalent
Agrippal
Fluad
Fluvirin
Fluvax
Key Companies Covered in the Report are as follows:
Sanofi Pasteur
GlaxoSmithKline(GSK)
Seqirus
AstraZenecca
Protein Sciences Corporation
Novavax
Daiichi–Sankyo
Mitsubishi Tanabe Pharma
BiondVax Pharmaceuticals Ltd
VaxInnate
Advertisements

About Globe Market Reports

Globe Market Reports offers top class market research reports of top publishers in the industry.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s